Clinical Trial Update: Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema. [Phase 4]

View source ↗

Summary

A Phase 4 post-marketing study assessing the safety and effectiveness of Beovu (brolucizumab) for diabetic macular edema has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• BEOVU (BROLUCIZUMAB)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Diabetic Macular Edema | Phase 4 | Status: COMPLETED